Otsuka Holdings Co., Ltd.

Cullinan Therapeutics and Taiho have a significant market opportunity with zipalertinib after successful results in the Phase I/II REZILIENT1 trial among previously treated non-small cell lung cancer

The US Food and Drug Administration is in the early phases of reconsidering the long-standing class-wide “black box” warning for antipsychotics citing increased mortality in older adults with dementia

With Spravato (esketamine) showing signs of solid growth during its fifth year on the market in 2024, Johnson & Johnson got another sign of confidence for the treatment-resistant depression drug o

Retooling a company to focus on a single asset is a high-risk strategy, and one that is generally taken when few other choices present themselves. Having taken this step last year, Kezar Life Science